The Biotech Stock Soaring 63% on Unprecedented Cancer Trial Results – Meet Janux Therapeutics
October PCE Data Sparks Debate on Inflation Progress and Fed Policy
The October reading of the Federal Reserve’s preferred inflation gauge, the Personal Consumption Expenditures (PCE) index, is giving mixed signals.
Stock Market Today: Dow Hits Record Highs as Russell 2000 Soars; Nvidia Weighs on Nasdaq
Small-Cap Stocks Rally: Russell 2000 Hits New Heights Amid Market Optimism
Business & Market Movers
The Biotech Stock Soaring 63% on Unprecedented Cancer Trial Results – Meet Janux Therapeutics
·Dec 04, 2024Breaking News
Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled “Low Glycemic Sugar Composition.”
Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative Laetose™ technology platform. The U.S. Patent and Trademark Office (USPTO) has issued U.S. patent # 11,898,184, entitled “Low Glycemic Sugar Composition” developed within this platform.
Bruush Oral Care Inc. and Arrive Technology Inc. Announce Agreement and Plan of Merger
scdadmin·Dec 15, 2023
Deep Dive & Research
Healthcare & Biotech
The Biotech Stock Soaring 63% on Unprecedented Cancer Trial Results – Meet Janux Therapeutics
On December 3, 2024, the company announced groundbreaking results for its lead drug candidate, JANX007, a tumor-activated T-cell engager targeting advanced-stage prostate cancer.
Join our newsletter
Read and share new perspectives on just about any topic. Everyone’s welcome.- 01Create a free account
- 02Write your story
Tech & Energy
Is MicroStrategy’s Bitcoin Frenzy Setting It Up For A Crash?
MicroStrategy has been making headlines once again, fueled by its audacious Bitcoin-centric strategy and a meteoric stock price rise of over 515% this year.
